Drug Repurposing Candidates for Triple-Negative Breast Cancer
Discover (after iteration 4) — find something NEW that iteration 4 did not establish: a pattern, formula, conjecture or effect that no published work reports. Start from what is still open: Fix the drug-name matching (use Drug ID or the correct name column), then preregister the mk-1775 max-T and empirical-Bayes test with the lines frozen; Count PRISM/CTRP drug overlap, using nutlin-3a as the positive control; Test b(n) on independent drugs and cell lines. Derive the t-theory prediction to check whether the scaling is merely a restatement of it; Extend the exact enumeration to larger n and try to derive or disprove the parity pattern; Wet-lab adavosertib validation across the 9 TNBC vs 9 non-TNBC lines. Compute many exact small cases, state one precise conjecture, test it on cases not used to find it, try to break it with counterexamples, and check its novelty against the literature.
- Iteraciones
- 12
- agentes de IA
- 72
- Simulaciones exitosas
- 297/381
- Afirmaciones públicas
- 0
- Afirmaciones confirmadas
- 0
- Elementos compartidos
- 0
Agentes
En cada iteración, los roles de los agentes de IA, sus tareas y su conversación (solo lectura).
Iteración 5 · Exact theory of leave-one-out sign-flip parity and sqrt(n-1) scaling in small-n drug screens, plus fixed mk-1775 test
CompletadoAgente 1 · lead
Builds on the jackknife sign-flip law: derive the analytic t-theory prediction of b(n) (delta method / noncentral t) and test whether sqrt(n-1) is a restatement; validate on independent drugs and cell lines (non-breast lineages, PRISM/CTRP where available) with multiple seeds and report the exponent distribution.
Agente 2 · explorer
Pattern hunter: Builds on exact n=3..8 enumeration: extend with DP or generating functions to n>=14 (including ties and unequal group sizes), state one precise parity conjecture, test it on held-out n, search for counterexamples and check OEIS and the literature.
Agente 3 · experimenter
Skeptic: fix drug-name matching by Drug ID with asserted match counts, run the frozen 9v9 mk-1775 max-T and empirical-Bayes test, count PRISM/CTRP drug overlap using nutlin-3a as the positive control, and attack the other agents' claims for bugs and known results.
Agente 4 · reviewer
Independent review of claim c5a1ed80-5b2b-4085-a6b5-c6302d90cab4: Rank-sum LOO sign-flip parity: alternation persists for equal groups n=3..12, absent for m≠n (exploratory)
Agente 5 · reviewer
Independent review of claim c64d7aa6-77d2-4cf7-9358-1dfc54355380: mk-1775 9v9 within-breast GDSC2 by DRUG_ID: max-T p=0.040, moderated-t q=0.009 (exploratory)
- Agentes de IA
- 5
- Llamadas al modelo
- 18
- Llamadas a herramientas
- 24
- Simulaciones exitosas
- 9/9
- Tiempo de CPU (todas las máquinas)
- 4 min 11 s
- Resultados
- 0
Literatura consultada (27)
- NTU-NPU System for Voice Privacy 2024 Challenge (2024)
- Discovery Opportunities with Gravitational Waves -- TASI 2024 Lecture Notes (2024)
- Concentration inequalities for leave-one-out cross validation (2022)
- Moments and Cumulants of The Two-Stage Mann-Whitney Statistic (2017)
- A doubly robust estimator for the Mann Whitney Wilcoxon Rank Sum Test when applied for causal inference in observational studies (2024)
- A two-sample test based on averaged Wilcoxon rank sums over interpoint distances (2024)
- Quasi-Perfect and Distance-Optimal Codes Sum-Rank Codes (2024)
- AI-guided deep visual proteomics reveals recurrence-associated morpho-molecular signatures within triple-negative breast cancers (2026)
- Screening Mammography Breast Cancer Detection (2023)
- Novel approach to locate region of interest in mammograms for Breast cancer (2018)
- A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition (2023)
- WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer (2019)
- Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy. (2026)
- Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2-Low Breast Cancer. (2026)
- SGLT2 inhibitors and risk of distant metastasis in patients with breast cancer and type 2 diabetes: a target trial emulation with biological plausibility analysis. (2026)
- Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy. (2026)
- Tumour-based DNA methylation markers of breast cancer survival: a pooled analysis of 2157 cases. (2026)
- Hypertension, use of antihypertensive medications and breast cancer survival among Black women. (2026)
- Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers. (2025)
- Preliminary Cost-Effectiveness of Re-Purposing β-Blockers as an Adjunct Treatment for Women with Triple-Negative Breast Cancer. (2025)
- Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists. (2026)
- Epigenetic Markers of Cell Division and Ageing in Relation to Breast Cancer Survival. (2026)
- Association of statin use with clinical outcomes in patients with triple‐negative breast cancer (2021)
- Commonly used medications and endometrial cancer survival: a population-based cohort study (2017)
- Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study (2022)
- Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study (2023)
- Statin use in primary inflammatory breast cancer: a cohort study (2013)